Search Result

Results for "

cyclin D1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (26) Akt (3) Androgen Receptor (1) Apoptosis (20) ATM/ATR (2) Aurora Kinase (1) Autophagy (5) Bcl-2 Family (4) Biochemical Assay Reagents (1) c-Met/HGFR (1) c-Myc (1) Casein Kinase (1) Caspase (2) CXCR (2) Deubiquitinase (2) EGFR (2) Endogenous Metabolite (1) Eukaryotic Initiation Factor (eIF) (1) FLT3 (1) FXR (1) GSK-3 (6) HDAC (1) HSP (2) JAK (2) JNK (1) Keap1-Nrf2 (2) MDM-2/p53 (3) MEK (2) MicroRNA (1) NF-κB (3) P-glycoprotein (1) PAK (1) Parasite (2) PARP (1) Phosphatase (1) PIN1 (1) PKC (2) RAR/RXR (1) Reactive Oxygen Species (3) RET (1) STAT (6) Survivin (2) Trk Receptor (1) VEGFR (1) Wnt (3) β-catenin (6)
By Research Areas:	Cancer (60) Infection (3) Inflammation/Immunology (6) Neurological Disease (5)

By Targets:

CDK (26)

Akt (3)

Androgen Receptor (1)

Apoptosis (20)

ATM/ATR (2)

Aurora Kinase (1)

Autophagy (5)

Bcl-2 Family (4)

Biochemical Assay Reagents (1)

c-Met/HGFR (1)

c-Myc (1)

Casein Kinase (1)

Caspase (2)

CXCR (2)

Deubiquitinase (2)

EGFR (2)

Endogenous Metabolite (1)

Eukaryotic Initiation Factor (eIF) (1)

FLT3 (1)

FXR (1)

GSK-3 (6)

HDAC (1)

HSP (2)

JAK (2)

JNK (1)

Keap1-Nrf2 (2)

MDM-2/p53 (3)

MEK (2)

MicroRNA (1)

NF-κB (3)

P-glycoprotein (1)

PAK (1)

Parasite (2)

PARP (1)

Phosphatase (1)

PIN1 (1)

PKC (2)

RAR/RXR (1)

Reactive Oxygen Species (3)

RET (1)

STAT (6)

Survivin (2)

Trk Receptor (1)

VEGFR (1)

Wnt (3)

β-catenin (6)

By Research Areas:

Cancer (60)

Infection (3)

Inflammation/Immunology (6)

Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: Cyclin G-associated Kinase (GAK) CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139450

Atirmociclib PF-07220060; CDK4/6-IN-6	CDK	Cancer
Atirmociclib (PF-07220060; example A94) is a potent CDK4/CDK6 inhibitor with a K_i of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively .

HY-145669

DIF-3 1 Publications Verification	CDK GSK-3	Cancer
DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in DLD-1 cells. DIF-3 exerts a strong antiproliferative effect on the human cervical cancer cell line HeLa by inducing cyclin D1 degradation and inhibiting cyclin D1 mRNA expression .

HY-147651

β-catenin-IN-4	β-catenin	Cancer
β-catenin-IN-4 (Compound 39) is a β-catenin inhibitor with a K_i of 0.64 μM. β-catenin-IN-4 reduces the protein expression levels of cyclin D1 and c-Myc .

HY-120458

LCAHA 1 Publications Verification LCA hydroxyamide	Deubiquitinase	Cancer
LCAHA (LCA hydroxyamide) is a deubiquitinase USP2a inhibitor with IC₅₀s of 9.7 μM and 3.7μM in Ub-AMC Assay and Di-Ub Assay, respectively. LCAHA destabilizes Cyclin D1 and induces G0/G1 arrest by inhibiting deubiquitinase USP2a .

HY-N0034

Arctiin 3 Publications Verification Arctii; NSC 315527; Arctigenin-4-glucoside	NF-κB	Inflammation/Immunology Cancer
Arctiin is an orally active inhibitor of NF-κB. Arctiin suppresses cyclin D1 protein expression in human tumor cells. Arctiin also reduces malondialdehyde and pro-inﬂammatory cytokines levels. Arctiin can used in study glomerulonephritis .

HY-125035

LCH-7749944 2 Publications Verification GNF-PF-2356	PAK Apoptosis	Cancer
LCH-7749944 (GNF-PF-2356) is a potent PAK4 inhibitor with an IC₅₀ of 14.93 μM. LCH-7749944 effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclin D1 pathway and induces apoptosis .

HY-111361

FN-1501 1 Publications Verification LT-171-861	CDK FLT3	Cancer
FN-1501 is a potent inhibitor of FLT3 and CDK, with IC₅₀s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.

HY-108907

SR-1277	Casein Kinase	Cancer
SR-1277 is a potent, selective and ATP competitive CK1δ/ε inhibitor, with IC₅₀s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9/cyclin K, with IC₅₀s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer .

HY-146389

Anticancer agent 50	MDM-2/p53 P-glycoprotein	Cancer
Anticancer agent 50 (compound 6) is a potent ABCB1 efflux pump modulator. Anticancer agent 50 shows cytotoxic effects and antiproliferative effects. Anticancer agent 50 decreases the expression of cyclin D1 and induces p53 expression. Anticancer agent 50 has the potential for the research of T-lymphoma .

HY-N0034R

Arctiin (Standard)	NF-κB	Inflammation/Immunology Cancer
Arctiin (Standard) is the analytical standard of Arctiin. This product is intended for research and analytical applications. Arctiin is an orally active inhibitor of NF-κB. Arctiin suppresses cyclin D1 protein expression in human tumor cells. Arctiin also reduces malondialdehyde and pro-in?ammatory cytokines levels. Arctiin can used in study glomerulonephritis .

HY-115932

Aurora kinase-IN-1	Aurora Kinase Apoptosis	Cancer
Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of aurora kinase. Aurora kinase-IN-1 upregulates the expression of G1 cell cycle inhibitory proteins including p21 and p27, and G1 progressive cyclin D1, and downregulates G1-to-S progressive cyclins, resulting in cell cycle arrest at the G1/S boundary. Aurora kinase-IN-1 also induces apoptosis. Aurora kinase-IN-1 is a lead compound for chemotherapeutic agents .

HY-12352

HJC0416	STAT Apoptosis	Cancer
HJC0416 is a potent and orally active STAT3 inhibitor. HJC0416 shows antiprolifeative activity and induces apoptosis. HJC0416 decreases the expression of p-STAT3 (Tyr-705), Cyclin D1 and increases the expression of cleaved caspase-3 protein. HJC0416 shows anti-tumor activity .

HY-112822

ON-013100 2 Publications Verification	CDK	Cancer
ON-013100, an antineoplastic agent, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.

HY-N4327

Eurycomalactone	NF-κB Apoptosis Akt Bcl-2 Family	Infection Inflammation/Immunology
Eurycomalactone is an active quassinoid could be isolated from Eurycoma longifolia Jack. Eurycomalactone is a potent NF-κB inhibitor with an IC₅₀ value of 0.5 μM. Eurycomalactone inhibits protein synthesis and depletes cyclin D1. Eurycomalactone enhances radiosensitivity through arrest cell cycle at G2/M phase and delayed DNA double-strand break repair. Eurycomalactone inhibits the activation of AKT/NF-κB signaling, induces apoptosis and enhances chemosensitivity to Cisplatin (HY-17394) .

HY-136726

CGP-82996 CINK4	CDK	Cancer
GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC₅₀s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer .

HY-10014

R547 2 Publications Verification	CDK GSK-3 Apoptosis	Cancer
R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively .

HY-111260

R547 mesylate	CDK GSK-3 Apoptosis	Cancer
R547 mesylate is a potent, selective and orally active ATP-competitive CDK inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively .

HY-119833

Rubone	MicroRNA	Cancer
Rubone, a chalcone analog, is a modulator of miR-34a. Rubone upregulates miR-34a expression in a p53 dependent manner, downregulates the downstream target Bcl-2 and Cyclin D1 expression, and suppresses hepatocellular carcinoma (HCC) growth in vivo. Rubone enhances the anticancer effect of Paclitaxel (PTX; HY-B0015) in PTX-resistant prostate cancer cell lines by reversing the expression of miR-34a downstream targets .

HY-111207

CA224	CDK Apoptosis	Cancer
CA224 (Compound 1) is a selective and orally active Cdk4–cyclin D1 inhibitor with an IC₅₀ of 6.2 µM. CA224 induces cell apoptosis and shows antitumor activity .

HY-18299A

Purvalanol A 2 Publications Verification NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-169002

PP5-IN-2	Phosphatase	Cancer
PP5-IN-2 is an orally active and selective protein phosphatase 5 (PP5) inhibitor with an IC₅₀ value of 0.9 μM. PP5-IN-2 activates p53 and downregulates cyclin D1 and MGMT, which shows potency in cell cycle arrest and reverses Temozolomide (TMZ) (HY-17364) resistance in the U87 MG cell line. PP5-IN-2 effectively inhibits tumor growth in the xenograft mouse model .

HY-139449

CDK4/6-IN-5	CDK	Cancer
CDK4/6-IN-5 is a potent CDK4 and CDK6 inhibitor with K_is of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively . (from patent WO2019207463A1 example A93).

HY-103380

NSC 625987 1 Publications Verification	CDK	Cancer
NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC₅₀ of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2 .

HY-10424

Milciclib 5+ Cited Publications PHA-848125	CDK Autophagy	Cancer
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC₅₀s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-112450

Olomoucine II	CDK	Cancer
Olomoucine II is a potent CDK inhibitor with IC₅₀ values of 0.06, 0.1, 0.45, 7.6, 19.8 µM for CDK9/cyclin T, CDK2/cyclin E, CDK7/cyclin H, CDK1/cyclin B, CDK4/cyclin D1, respectively. Olomoucine II shows antiproliferative activity .

HY-147409

Ulecaciclib	CDK	Cancer
Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with K_i values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .

HY-115992

CDK4/6-IN-9	CDK	Cancer
CDK4/6-IN-9 (compound 10) is a selective CDK4/6 inhibitor with an IC₅₀ of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research .

HY-111932

Indirubin-5-sulfonate	CDK GSK-3	Cancer
Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC₅₀ values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively . Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β .

HY-129694

Lenoremycin Ro 21-6150; Antibiotic A-130-A	β-catenin CDK Reactive Oxygen Species	Cancer
Lenoremycin (Ro 21-6150) is a microbial metabolite. Lenoremycin decreases β-catenin and cyclin D1 proteins levels. Lenoremycin decreases cancer stem cells (CSCs) populations via inducing reactive oxygen species production .

HY-16559A

Riviciclib P276-00 free base	CDK	Cancer
Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .

HY-16559

Riviciclib hydrochloride 3 Publications Verification P276-00	CDK Apoptosis	Cancer
Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .

HY-112799

DK419	Wnt β-catenin	Cancer
DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC₅₀ of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK .

HY-P4979

Cdc25A (80-93) (human)	Biochemical Assay Reagents	Cancer
Cdc25A (80-93) (human) is a polypeptide that controls the cell proliferation and tumorigenesis by a change in expression of proteins involved in cyclin D1 regulation and G1/S transition. Cdc25A (80-93) (human) can be used in cancer research .

HY-15504A

RGB-286638 free base 2 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, **cyclin D1-CDK4*, cyclin* E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-15504

RGB-286638 2 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, **cyclin D1-CDK4*, cyclin* E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-157148

1D228	c-Met/HGFR Trk Receptor	Cancer
1D228 is a c-Met/TRK inhibitor with antitumor activity. 1D228 inhibits cyclin D1 to induce G0/G1 arrest and inhibit cancer cell proliferation and migration. 1D228 can be used in the study of gastric, liver and vascular tumors .

HY-10969

Obatoclax Mesylate 5+ Cited Publications GX15-070 Mesylate	Bcl-2 Family Autophagy Parasite	Infection Cancer
Obatoclax Mesylate (GX15-070 Mesylate), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a K_i of 220 nM for BCL-2 . Obatoclax Mesylate induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax Mesylate has anti-cancer and broad-spectrum antiparasitic activity .

HY-10969A

Obatoclax GX15-070	Bcl-2 Family Autophagy Parasite	Infection Cancer
Obatoclax (GX15-070), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a K_i of 220 nM for BCL-2 . Obatoclax induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax has anti-cancer and broad-spectrum antiparasitic activity .

HY-119966

CCT036477	Wnt β-catenin	Cancer
CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2) .

HY-N1930

(-)-Hinesol Hinesol	Apoptosis	Cancer
(-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer .

HY-100900

ML364 Maximum Cited Publications 13 Publications Verification	Deubiquitinase	Cancer
ML364 is a selective ubiquitin specific peptidase 2 (USP2) inhibitor (IC₅₀=1.1 μM) with anti-proliferative activity, which direct binds to USP2 (K_d=5.2 μM), induces an increase in cellular cyclin D1 degradation and causes cell cycle arrest. ML364 increases the levels of mitochondrial ROS and decreases in the intracellular content of ATP .

HY-113308

Taurolithocholic acid	Others	Others
Taurolithocholic acid is a bile acid that has the activity of increasing cell viability, inducing the S phase of the cell cycle, and promoting DNA synthesis in a concentration-dependent manner in the intrahepatic cholangiocarcinoma cell line RMCCA-1. It can also increase the phosphorylation of EGFR and ERK 1/2 and the expression of cyclin D1 in RMCCA-1 cells, and its induced RMCCA-1 cell growth can be inhibited by specific antagonists and inhibitors.

HY-N6953

Garcinone D 2 Publications Verification	STAT Keap1-Nrf2 Reactive Oxygen Species	Neurological Disease
Garcinone D, a natural xanthone from mangosteen, promotes the proliferation of C17.2 neural stem cell. Garcinone D increases the protein levels of phosphorylated signal transducer and activator of transcription 3 (p-STAT3), Cyclin D1 and nuclear factor erythroid 2-related factor (Nrf2), heme oxygenase-1 (HO-1) in concentration- and time- dependent manners .

HY-N6954

Garcinone C 1 Publications Verification	ATM/ATR STAT CDK	Cancer
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, Stat3 and CDK7. Garcinone C significantly inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner .

HY-18981

Decursin 1 Publications Verification (+)-Decursin	PKC Apoptosis CXCR	Neurological Disease Inflammation/Immunology Cancer
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

HY-161826

Antitumor agent-174	β-catenin HSP CDK c-Myc	Cancer
Antitumor agent-174 (Compound 10) directly engages the N-terminal site of Hsp90 and promotes the degradation of β-catenin, thereby suppressing the Wnt/β-catenin signaling. Antitumor agent-174 effectively inhibits proliferation, induce S and G2/M phases arrest and block the clonogenic ability in CRC cells. Antitumor agent-174 down-regulates CDK1, Cyclin D1, c-Myc, Cyclin B1, and Cyclin A2, and upregulaties P21 proteins. Antitumor agent-174 has significant anti-tumor efficacy against colorectal cancer (CRC) with excellent pharmacokinetics and low toxicity .

HY-N6954R

Garcinone C (Standard)	ATM/ATR STAT CDK	Cancer
Garcinone C (Standard) is the analytical standard of Garcinone C. This product is intended for research and analytical applications. Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, Stat3 and CDK7. Garcinone C significantly inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time? and dose?dependent manner .

HY-150597

HDAC-IN-46	HDAC Apoptosis	Cancer
HDAC-IN-46 (compound 12c) is a potent HDAC inhibitor with an IC₅₀ value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC) .

HY-W010995

2,5-Dimethylcelecoxib	Wnt Survivin β-catenin	Cancer
2,5-Dimethylcelecoxib is an analogue of celecoxib (HY-14398) with anticancer activity but without COX-2 inhibitory activity. 2,5-Dimethylcelecoxib exerts its anti-cancer cell proliferation effect by inhibiting the core mechanism of the Wnt/β-catenin signaling pathway. 2,5-Dimethylcelecoxib also inhibits T-cell factor-dependent transcriptional activity and inhibits expression of the Wnt/β-catenin target gene products cyclin D1 and survivin .

HY-124843

LLL3 CLT-005	STAT Apoptosis	Cancer
LLL3 (CLT-005) is a STAT3 inhibitor. LLL3 inhibits dimerization and phosphorylation of STAT3, thereby preventing intraconuclear transfer of STAT3 and inhibits the expression of STAT3 dependent genes, which encode proteins such as Bcl-xL and cyclin D1. In addition, LLL3 can induce cell growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells via the caspase pathway. LLL3 can be used in the study of STAT3 persistent activation types of cancer .

Cat. No.	Product Name	Target	Research Area

HY-P4979

Cdc25A (80-93) (human)	Biochemical Assay Reagents	Cancer
Cdc25A (80-93) (human) is a polypeptide that controls the cell proliferation and tumorigenesis by a change in expression of proteins involved in cyclin D1 regulation and G1/S transition. Cdc25A (80-93) (human) can be used in cancer research .

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	Sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P72119

	CCND1 Protein, Human (His) AI327039; B cell leukemia 1; B-cell lymphoma 1 protein; BCL 1; BCL-1; BCL-1 oncogene; BCL1; BCL1 oncogene; ccnD1; CCND1/FSTL3 fusion gene; CCND1/FSTL3 fusion gene; included; CCND1/IGHG1 fusion gene; CCND1/IGLC1 fusion gene; CCND1_HUMAN; cD1; Cyl 1; D11S287E; G1/S specific cyclin D1; G1/S-specific cyclin-D1; PRAD1; PRAD1 oncogene; U21B31	Human	E. coli
	The CCND1 protein is a regulatory component of the cyclin D1-CDK4 complex that coordinates phosphorylation and RB family inhibition to regulate the G(1)/S transition. This promotes the dissociation of E2F from the RB/E2F complex and promotes the transcription of E2F target genes critical for G(1) phase progression. CCND1 Protein, Human (His) is the recombinant human-derived CCND1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of CCND1 Protein, Human (His) is 295 a.a., with molecular weight of ~37.7 kDa.

HY-P701366

	CDK6-CCND1 Heterodimer Protein, Human (Sf9) CDK6; CCND1; cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D1; B-cell lymphoma 1 protein; BCL-1; BCL-1 oncogene; PRAD1 oncogene	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND1 Heterodimer protein, expressed by Sf9 insect cells , with tag free.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80098

	Cyclin D1 Antibody (YA485)	WB, ICC/IF, IHC-P, IP	Human, Mouse, Rat
	Cyclin D1 Antibody (YA485) is a non-conjugated and Rabbit origined monoclonal antibody about 34 kDa, targeting to Cyclin D1. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P80633

	Cyclin D1 Antibody CCND1; BCL1; D11S287E; PRAD1; U21B31; cyclin D1	WB, IHC-P, IP	Human, Mouse, Rat
	Cyclin D1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 34 kDa, targeting to Cyclin D1. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks